MTM and DAKO link up on cancer diagnostics:
This article was originally published in Clinica
German company MTM Laboratories and DAKO, of Copenhagen, Denmark, have formed a cancer screening licensing and product development deal. DAKO gets exclusive, worldwide rights to MTM's CINtec molecular technology, which is aimed at early identification of cervical cancer. The two companies plan to develop the technology for the diagnosis of other types of tumours. MTM will get undisclosed upfront, milestone, R&D and royalty payments. DAKO has considerable experience in moving cell-based diagnostics through the regulatory process to market and will significantly shorten MTM's time to market, Heidelberg-based MTM says.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.